Frontlight ResearchEarly access
Active, not recruitingPhase 1
Study of a birth control pill taken with ganfeborole, a tuberculosis medicine
Tests how ganfeborole affects birth control pill levels in women who cannot become pregnant.
Key facts
- Who runs it
- Glaxosmithkline Research & Development Limited
- Where
- Madrid, SpainSee the site
- Trial code
- Registry title
- A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 28 people, planned
- Started
- 20 Aug 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 7 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women who cannot become pregnant. It studies how a birth control pill behaves in the body alone and together with ganfeborole.
- Age
- 18 years or older
- Sex
- Women only
Where in Spain
- Hospital Universitario La PazMadrid, SpainNo longer taking part
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Study of a birth control pill taken with ganfeborole, a tuberculosis medicineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 7 October 2026